Digistain ® - Leading digital transformation in cancer diagnostics - radically faster gold standard risk scoring analytics at a dramatically lower cost
A Digital Solution To Cancer Grading And Prognosis approved by the UK’s Medicines & Healthcare products Regulatory Agency (MHRA), DIGISTAIN® is a patented risk profiling test for hormone receptor-positive breast cancer patients.
Digistain’s easy-to-read report provides both physician and patient clear actionable information to help determine the best course of treatment and indeed whether cytotoxic therapy in addition to hormone therapy is required.
The MHRA approved DIGISTAIN technology is based on 15 years of research and development pioneered by respected cancer research scientists at Imperial College with Professor Chris Phillips of the Biomedical Optics Division and Cancer Research UK (CRUK) with Professor Sir Nicholas Wright of Barts Hospital London, Head of Histopathology at CRUK and ex-president of the Pathological Society of Great Britain.
Company Details
- Employees
- 22
- Address
- Unit 101, Interchange Business Park,, Howard Way,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://digistain.co.uk
- HQ
- Newport Pagnell,
Digistain® Questions
Digistain®'s website is https://digistain.co.uk
Digistain®'s LinkedIn profile is https://uk.linkedin.com/company/digistain
Digistain® has
22 employees.
View email and phone details for 22
employees at Digistain®.
Digistain®'s industry is
Biotechnology Research
Digistain®'s top competitors are
Mirvie,
Rea Diagnostics Sa,
Novoic,
Pocdoc,
Acorai,
Harrison.ai,
Fluoretiq Limited,
Congenica,
Starling (Yc W22),
Untap Health.
Digistain®'s categories are Biotechnology Research
